Equity · Healthcare
DSGN
NASDAQDesign Therapeutics (DSGN)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 754.3M USD
- Revenue, year to Dec 2025
- 0 USD
- EPS, diluted, year to Dec 2025
- −1.22 USD
- 52-week range
- 3.82 USD – 16 USD
- Avg volume
- 206.5K
as of Jul 22, 2026
Have Design Therapeutics (DSGN) insiders bought or sold shares recently?
DSGN's newest Form 4 filing is dated 9 December 2025: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 09 Dec 2025 | Shah PratikPresident, CEO and Chairperson | Award | 525,000 |
Which funds hold Design Therapeutics (DSGN)?
7 of the 45 institutional funds we track reported a Design Therapeutics position for the quarter ended 30 Sep 2026 — a combined 75.9M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Baker Bros. Advisors | Held (±25%) | 2,988,144 | 37.6M USD | +11.6% |
| Point72 Asset Management | Held (±25%) | 2,317,682 | 29.1M USD | −2.1% |
| Renaissance Technologies | Held (±25%) | 301,800 | 3.8M USD | −22.2% |
| D. E. Shaw & Co. | Held (±25%) | 186,071 | 2.3M USD | −4.9% |
| AQR Capital Management | Added | 153,190 | 1.9M USD | +115.4% |
| Citadel Advisors | Held (±25%) | 76,300 | 959K USD | −6.9% |
| Two Sigma Investments | Trimmed | 17,200 | 216K USD | −47.8% |
| Balyasny Asset Management | Exited | |||
| Millennium Management | Exited |
What has been filed or recorded for Design Therapeutics (DSGN)?
The filings we hold for Design Therapeutics, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 29 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 734 shares | 8K USD notional · 0.001% of shares out |
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 4 shares | 43 USD notional · <0.001% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 80,485 shares | 830K USD notional · 0.126% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 618 shares | 7K USD notional · 0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 682 shares | 8K USD notional · 0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 342 shares | 4K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.32 USD | |
| 30 Sep 2026 | Financials | Total assets | 216.8M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 202.2M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.32 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.29 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.22 USD | |
| 31 Dec 2025 | Financials | Revenue | 0 USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −69.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.22 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.30 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.34 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.31 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.88 USD |
What do people ask about Design Therapeutics (DSGN)?
What is Design Therapeutics’ market cap?754.3M
Design Therapeutics is worth 754.3M USD by market value as of 22 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is Design Therapeutics’ revenue?0
Design Therapeutics reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Design Therapeutics insiders bought or sold shares recently?
No Design Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 9 Dec 2025 (SEC Form 4). See Insiders
Which funds own Design Therapeutics?7 of 45
7 of the 45 funds we track reported a Design Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Point72 Asset Management and Renaissance Technologies. See Funds
When did Design Therapeutics last report earnings?−0.32
Design Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.32 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words